Madan Jagasia

June 13, 2019

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC’s Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

By Tom Wilemon
The Vanderbilt Ingram Cancer Center (Neil Brake/Vanderbilt)
November 2, 2018

Cancer Center among best in nation for stem cell transplant survival

Vanderbilt-Ingram Cancer Stem Cell Transplant ranks among the best in the nation for donor stem cell transplant survival rates among large centers, according to an annual report.

By Tom Wilemon
August 30, 2018

Using light to fight GVHD

Extracorporeal photopheresis treatment for stem cell transplant-related complications produces a response in up to 60 percent of patients.

By Leigh MacMillan
June 12, 2018

Jagasia to succeed Neuss as VICC Chief Medical Officer

After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverly Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.

By VUMC News and Communications
January 25, 2018

Directorships honor VUMC’s critical missions

Vanderbilt University Medical Center (VUMC) on Monday held its first Directorship Celebration to honor and support eight of its leaders in clinical care, research, education and administration.

By Bill Snyder
October 25, 2017

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

By VUMC News and Communications
March 3, 2016

First VICC cancer patient treated with new immunotherapy

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.
By VUMC News and Communications
December 11, 2014

Visit unites stem cell transplant patient, donor for first time

When Darlena Clark of Hendersonville, Tennessee, saw Jon Strong for the first time at Nashville International Airport she, “just grabbed him and hugged him and just held on.”
By VUMC News and Communications
April 12, 2012

Targeting post-transplant diabetes

Targeting diabetes that develops after a stem cell transplant may help moderate graft-vs.-host disease, an adverse effect of the procedure, and improve outcomes.
By VUMC News and Communications